Payden & Rygel Danaher Corp Transaction History

Payden & Rygel

$1.21 Billion
Q3 2025

A detailed history of Payden & Rygel transactions in Danaher Corp stock. As of the latest transaction made, Payden & Rygel holds 2,000 shares of DHR stock, worth $440,880. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,000

Previous 80,600 97.52%

Holding current value

$440,880

Previous $15.9 Million 97.51%

% of portfolio

0.03%

Previous 1.32%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$181.46 - $212.2 $14.3 Million - $16.7 Million	-78,600 Reduced 97.52%	2,000 $397,000
Q2 2025 Aug 07, 2025	BUY	$174.64 - $205.16 $384,207 - $451,352	2,200 Added 2.81%	80,600 $15.9 Million
Q1 2025 May 15, 2025	BUY	$201.62 - $250.59 $15.6 Million - $19.4 Million	77,400 Added 7740.0%	78,400 $16.1 Million
Q2 2024 Oct 07, 2024	SELL	$235.51 - $267.98 $12.4 Million - $14.1 Million	-52,580 Reduced 98.13%	1,000 $250,000
Q4 2023 Feb 12, 2024	SELL	$185.1 - $233.13 $5.98 Million - $7.53 Million	-32,280 Reduced 97.0%	1,000 $231,000

Q3 2023 Oct 07, 2024	BUY	$233.08 - $265.59 $12.3 Million - $14 Million	52,580 Added 5258.0%	53,580 $11.8 Million
Q2 2023 Aug 10, 2023	SELL	$224.99 - $256.14 $12.4 Million - $14.1 Million	-55,000 Reduced 62.3%	33,280 $7.99 Million
Q1 2023 May 10, 2023	BUY	$239.75 - $277.0 $239,750 - $277,000	1,000 Added 1.15%	88,280 $22.3 Million
Q4 2022 Feb 13, 2023	BUY	$241.42 - $282.29 $21.1 Million - $24.6 Million	87,280 New	87,280 $23.2 Million
Q1 2021 May 13, 2021	SELL	$212.38 - $245.9 $127,428 - $147,540	-600 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$79.29 - $88.45 $47,574 - $53,070	600	600 $51,000

Others Institutions Holding DHR

# of Institutions

2,484

Shares Held

571M

Call Options Held

5.44M

Put Options Held

3.44M

View Full List

About DANAHER CORP

Ticker DHR
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 727,963,008
Market Cap $160B
Description
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automati...

More about DHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel with notifications on news.

Account